Development of DOTA-Rituximab to be Labeled with <sup>90</sup>Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
| Author | Fariba Johari doha | en |
| Author | Siyavash Rahmani | en |
| Author | Pedram Rikhtechi | en |
| Author | Samira Rasaneh | en |
| Author | Zahra Sheikholislam | en |
| Author | Soraya Shahhosseini | en |
| Issued Date | 2017-04-30 | en |
| Abstract | NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radionuclide coupled to anti-CD20 antibody. The association of beta emitter radionuclide to rituximab enhances its therapeutic efficacy. The cells which lack antigen or cells which cannot be reached due to poor vascularization and intratumoral pressure in a bulky tumor would be irradiated and killed by cross fire effect of beta emitter. 90Y, a pure high energy β-emitter with a half-life of 64 h, a maximum energy of 2.28 MeV, and maximum board of 11.3 mm in tissue is radionuclide of choice for radioimmunotherapy of outpatient administration. | en |
| DOI | https://doi.org/10.22037/ijpr.2017.2109 | en |
| Keyword | B-cell Non-Hodgkin Lymphoma | en |
| Keyword | radioimmunotherapy | en |
| Keyword | 90-Y | en |
| Keyword | Rituximab | en |
| Keyword | Immunoreactivity | en |
| Publisher | Brieflands | en |
| Title | Development of DOTA-Rituximab to be Labeled with <sup>90</sup>Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma | en |
| Type | Original Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- ijpr-16-619.pdf
- Size:
- 629.89 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF